Skip to main content
. 2006 Jan 19;116(2):528–535. doi: 10.1172/JCI24742

Figure 9.

Figure 9

A novel vitamin D analog, DD281, inhibits osteoclast differentiation and increases BMD more potently than 1α,25(OH)2D3 in vivo. (A) Structures of 1α,25(OH)2D3 and its analog, DD281. (B) Ovariectomized (OVX) C57BL/6J mice were treated orally with the indicated doses of 1α,25(OH)2D3 or its analog DD281 for 4 weeks, and urinary calcium excretion was determined for the final 24 hours. *P < 0.05 versus OVX group with vehicle treatment, #P < 0.05 versus sham group, n = 8 each group. (C) BMD at the lumbar vertebrae was determined. *P < 0.05 versus OVX group with vehicle treatment, **P < 0.005 versus OVX group with vehicle treatment, ***P < 0.0005 versus OVX group with vehicle treatment, #P < 0.05 versus sham group, n = 8 each group.

HHS Vulnerability Disclosure